德達醫療完成1億美元融資 獲太古(00019.HK)領投
德達醫療今日宣布完成最新一輪融資,規模超1億美元,由太古(00019.HK)領投,現有股東斯道資本繼續支持。完成後,太古將成為德達醫療第二大投資方。
德達醫療將利用所募集資金加速其心血管戰略落地,並打造全新業務亮點。
德達醫療由背靠富達集團的全球性風險投資機構斯道資本投資創建,響應中國醫療改革,並與公立醫療體系緊密協作。如今,德達醫療已搭建起以心血管疾病為核心的綜合醫院網絡,包括上海德達醫院,以及門診部德西診所 。
上海德達醫院醫療院長孫立忠指,利用這筆資金,可以擴展臨床團隊,推出胸部腫瘤等新專科,並最終擴大服務範圍。
太古股份有限公司主席白德利指,公司的策略是在已經擁有業務的主要城市群中,物色專為中產階級提供高質量醫療服務的機構,並尋求合作機會。上海和長三角是整個集團 (包括太古地產(01972.HK))重要業務增長區域之一,因此對德達醫療的投資符合集團的策略。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.